Literature DB >> 27381029

If PBMs Guard Access to Drugs, Then Quis Custodiet Ipsos Custodies? (Who Will Guard the Guardians?).

Alan W Carter1,2, Lutz Heinemann3.   

Abstract

Insulin prices in the United States have risen dramatically in recent years, yet pharmacies cannot provide a stable price for a given insulin due to factors that are not widely understood. This commentary discusses the complex and obscure factors that drive today's insulin prices with a discussion of the other players, besides the insulin manufacturer, who benefit from higher prices. An open discussion is critical regarding this drug and others that are essential to the lives of millions of people with diabetes. We'll also explore whether the market introduction of biosimilar insulin will impact insulin prices.
© 2016 Diabetes Technology Society.

Entities:  

Keywords:  biosimilar insulin; insulin; quality; therapy

Mesh:

Substances:

Year:  2016        PMID: 27381029      PMCID: PMC5094334          DOI: 10.1177/1932296816658056

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  4 in total

1.  Costs Associated With Using Different Insulin Preparations.

Authors:  Tracy Tylee; Irl B Hirsch
Journal:  JAMA       Date:  2015-08-18       Impact factor: 56.272

2.  Quality Control of Insulins and Biosimilar Insulins: What Do We Know?

Authors:  Alan W Carter; Lutz Heinemann; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2016-06-28

3.  Biosimilar Insulin and Costs: What Can We Expect?

Authors:  Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2015-09-08

4.  In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?

Authors:  Alan W Carter
Journal:  J Diabetes Sci Technol       Date:  2016-08-22
  4 in total
  3 in total

1.  Inhaled Insulin: Dead Horse or Rising Phoenix?

Authors:  Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2017-12-13

2.  Insulin Storage: A Critical Reappraisal.

Authors:  Lutz Heinemann; Katarina Braune; Alan Carter; Amin Zayani; Laura A Krämer
Journal:  J Diabetes Sci Technol       Date:  2020-01-29

Review 3.  Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?

Authors:  Laura N McEwen; Sarah Stark Casagrande; Shihchen Kuo; William H Herman
Journal:  Curr Diab Rep       Date:  2017-09       Impact factor: 4.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.